Download the Appendix

References

  1. National Cancer Institute: SEER stat fact sheets: Melanoma of the Skin. seer.cancer.gov/statfacts/html/melan.html
  2. Ribas A, Hamid O, Daud A, et al.: Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600-1609, 2016
  3. Topalian SL, Sznol M, McDermott DF, et al.: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030, 2014
  4. Schadendorf D, Hodi FS, Robert C, et al.: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889-1894, 2015
  5. Postow M, Chesney J, Pavlick A, et al.: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL). Presented at the 107th Annual Meeting of the American Association for Cancer Research, New Orleans, LA, April 16-20, 2016 (abstr CT002)
  6. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al.: Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med [epub ahead of print on October 7, 2016]
  7. WHO International Agency for Research on Cancer: GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. globocan.iarc.fr/Default.aspx
  8. Herbst RS, Baas P, Kim DW, et al.: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-1550, 2016
  9. Reck M, Rodriguez-Abreu D, Robinson AG, et al.: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med [epub ahead of print on October 8, 2016]
  10. Socinski M, Creelan B, Hom L, et al: CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice of platinum-based doublet chemotherapy as first-line therapy for stage IV/reccurrent programmed death ligand 1-positive NSCLC. Presented at the 2016 European Society for Medical Oncology, Copenhagen, Denmark, October 7-11, 2016 (abstr LBA7-PR)
  11. US Food and Drug Administration: Atezolizumab (TECENTRIQ). fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm
  12. US Food and Drug Administration: Pembrolizumab (KEYTRUDA) checkpoint inhibitor. fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526430.htm
  13. National Cancer Institute: SEER stat fact sheets: Bladder cancer. seer.cancer.gov/statfacts/html/urinb.html
  14. American Cancer Society: Bladder cancer. cancer.org/cancer/bladdercancer/
  15. US Food and Drug Administration: FDA approves new, targeted treatment for bladder cancer. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm
  16. Rosenberg JE, Hoffman-Censits J, Powles T, et al.: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387:1909-1920, 2016
  17. Business Wire: Merck’s KEYNOTE-045 studying KEYTRUDA® (pembrolizumab) in advanced bladder cancer (urothelial cancer) meets primary endpoint and stops early. http://www.businesswire.com/news/home/20161021005182/en/Merck%E2% 80%99s-KEYNOTE-045-Studying-KEYTRUDA%C2% AE-pembrolizumab-Advanced-Bladder
  18. Balar A, Bellmunt J, O’Donnell PH, et al.: Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study. Presented at the 2016 European Society for Medical Oncology, Copenhagen, Denmark, October 7-11, 2016 (abstr LBA32-PR)
  19. Ferlay J, Soerjomataram I, Dikshit R, et al.: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015
  20. National Cancer Institute: SEER stat fact sheets: Oral cavity and pharynx cancer. seer.cancer.gov/statfacts/html/oralcav.html
  21. Ferris RL, Blumenschein G Jr, Fayette J, et al.: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med [epub ahead of print on October 8, 2016]
  22. US Food and Drug Administration: Nivolumab for SCCHN. fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm528920.htm
  23. National Cancer Institute: SEER stat fact sheets: Ovarian cancer. seer.cancer.gov/statfacts/html/ovary.html
  24. Hamanishi J, Mandai M, Ikeda T, et al.: Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:4015-4022, 2015
  25. National Cancer Institute: SEER stat fact sheets: Hodgkin lymphoma. seer.cancer.gov/statfacts/html/hodg.html
  26. US Food and Drug Administration: Nivolumab (Opdivo) for Hodgkin lymphoma. fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501412.htm
  27. Roemer MG, Advani RH, Ligon AH, et al.: PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34:2690-2697, 2016
  28. Younes A, Santoro A, Shipp M, et al.: Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283-1294, 2016
  29. Armand P, Shipp MA, Ribrag V, et al: Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34:3733-3739, 2016
  30. Zaretsky JM, Garcia-Diaz A, Shin DS, et al.: Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375:819-829, 2016
  31. Roberts SA, Gordenin DA: Hypermutation in human cancer genomes: Footprints and mechanisms. Nat Rev Cancer 14:786-800, 2014
  32. Le DT, Uram JN, Wang H, et al.: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
  33. Bouffet E, Larouche V, Campbell BB, et al..: Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206-2211, 2016
  34. Nghiem PT, Bhatia S, Lipson EJ, et al.: PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374:2542-2552, 2016
  35. Kaufman HL, Russell J, Hamid O, et al.: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374-1385, 2016
  36. Antoniou AC, Pharoah PP, Smith P, et al.: The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91:1580-1590, 2004
  37. Song H, Dicks E, Ramus SJ, et al.: Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol 33:2901-2907, 2015
  38. Holter S, Borgida A, Dodd A, et al.: Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33:3124-3129, 2015
  39. Vasen H, Ibrahim I, Ponce CG, et al.: Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. J Clin Oncol 34:2010-2019, 2016
  40. Yurgelun MB, Allen B, Kaldate RR, et al.: Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 149:604-613.e20, 2015
  41. Zhang J, Walsh MF, Wu G, et al.: Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373:2336-2346, 2015
  42. Fransen M, Karahalios A, Sharma N, et al.: Non-melanoma skin cancer in Australia. Med J Aust 197:565-568, 2012
  43. Guy GP Jr, Machlin SR, Ekwueme DU, et al.: Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011. Am J Prev Med 48: 183-187, 2015
  44. Chen AC, Martin AJ, Choy B, et al.: A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 373:1618-1626, 2015
  45. Zorogastua K, Erwin D, Thelemaque L, et al.: Intrinsic factors of non-adherence to breast and cervical cancer screenings among Latinas. J Racial Ethn Health Disparities 3:658-666, 2016
  46. National Cancer Institute: SEER stat fact sheets: Acute myeloid leukemia (AML). seer.cancer.gov/statfacts/html/amyl.html
  47. Stone RM, Mandrekar S, Sanford BL, et al.: The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Blood 126:6, 2015.
  48. National Cancer Institute: SEER stat fact sheets: Acute lymphocytic leukemia (ALL). seer.cancer.gov/statfacts/html/alyl.html
  49. Kantarjian HM, DeAngelo DJ, Stelljes M, et al.: Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375: 740-753, 2016
  50. Shaw AT, Gandhi L, Gadgeel S, et al.: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol 17:234-242, 2016
  51. US Food and Drug Administration: FDA approves new oral therapy to treat ALK-positive lung cancer. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm
  52. Nokihara H, Kondo M, Kim YH, et al.: Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. J Clin Oncol 34, 2016 (suppl; abstr 9008)
  53. National Cancer Institute: SEER stat fact sheets: Myeloma. seer.cancer.gov/statfacts/html/mulmy.html
  54. Palumbo A, Chanan-Khan AAA, Weisel K, et al.: Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. J Clin Oncol 34, 2016 (suppl; abstr LBA4)
  55. Cristofanilli M, Turner NC, Bondarenko I: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425-439, 2016
  56. Finn RS, Martin M, Rugo HS, et al.: PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal womenwith ER+/HER2–advanced breast cancer (ABC). J Clin Oncol 34, 2016 (suppl; abstr 507)
  57. Hortobagyi GN, Stemmer SM, Burris HA, et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738-1748, 2016
  58. US Food and Drug Administration: Palbociclib (IBRANCE capsules). fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm487080.htm
  59. National Cancer Institute: SEER stat fact sheets: Kidney and renal pelvis cancer. seer.cancer.gov/statfacts/html/kidrp.html
  60. Choueiri TK, Escudier B, Powles T, et al.: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917-927, 2016
  61. US Food and Drug Administration: Cabozantinib (CABOMETYX). fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm
  62. Janowitz T, Welsh SJ, Zaki K, et al.: Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol 40:482-491, 2013
  63. Ravaud A, Motzer RJ, Pandha HS, et al.: Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375:2246-2254, 2016
  64. Haas NB, Manola J, Uzzo RG, et al.: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renalcell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-2016, 2016
  65. Moore KN, Martin LP, Seward SM, et al.: Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. J Clin Oncol 33, 2015 (suppl; abstr 5518)
  66. Buckner JC, Shaw EG, Pugh SL, et al.: Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374:1344-1355, 2016
  67. Park JR, Kreissman SG, London SG, et al.: A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children’s Oncology Group (COG) study. J Clin Oncol 34, 2016 (suppl; abstr LBA3)
  68. Venook AP, Niedzwiecki D, Innocenti F, et al.: Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 34, 2016 (suppl; abstr 3504)
  69. Tejpar S, Stintzing S, Ciardiello F, et al.: Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol [epub ahead of print on October 10, 2016]
  70. Petrelli F, Tomasello G, Borgonovo K, et al.: Prognostic survival associated with left-sided vs right-sided colon cancer. JAMA Oncol [epub ahead of print on October 27, 2016]
  71. National Cancer Institute: SEER stat fact sheets: Pancreas cancer. seer.cancer.gov/statfacts/html/pancreas.html
  72. Neoptolemos JP, Palmer D, Ghaneh P, et al.: ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 34, 2016 (suppl; abstr LBA4006)
  73. Lancet JE, Uy GL, Cortes JE, et al.: Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. J Clin Oncol 34, 2016 (suppl; abstr 7000)
  74. Fleshman J, Branda M, Sargent DJ, et al.: Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: The ACOSOG Z6051 randomized clinical trial. JAMA 314:1346-1355, 2015
  75. Stevenson AR, Solomon MJ, Lumley JW, et al.: Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: The ALaCaRT randomized clinical trial. JAMA 314:1356-1363, 2015
  76. Goss PE, Ingle JN, Pritchard KI, et al.: Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209-219, 2016
  77. Pan H, Gray RG, Davies C, et al.: Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). J Clin Oncol 34, 2016 (suppl; abstr 505)
  78. Navari RM, Qin R, Ruddy KJ, et al.: Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134-142, 2016
  79. Basch E, Deal AM, Kris MG, et al.: Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol 34:557-565, 2016
  80. Castaldi M, Safadjou S, Elrafei T, et al.: A multidisciplinary patient navigation program improves compliance with adjuvant breast cancer therapy in a public hospital. Am J Med Qual [epub ahed of print on June 29, 2016]
  81. Kaphingst KA, Blanchard M, Milam L, et al.: Relationships between health literacy and genomics-related knowledge, self-efficacy, perceived importance, and communication in a medically underserved population. J Health Commun 21, 58-68, 2016 (suppl 1)
  82. National Cancer Institute: SEER stat fact sheets: Prostate cancer. seer.cancer.gov/statfacts/html/prost.html
  83. Hamdy FC, Donovan JL, Lane JA, et al.: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415-1424, 2016
  84. Shain AH, Yeh I, Kovalyshyn I, et al.: The genetic evolution of melanoma from precursor lesions. N Engl J Med 373:1926-1936, 2015
  85. Wheler JJ, Janku F, Naing A, et al.: Cancer therapy directed by comprehensive genomic profiling: A single center study. Cancer Res 76:3690-3701, 2016
  86. Hainsworth JD, Meric-Bernstam F, Swanton C, et al.: Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. J Clin Oncol 34, 2016 (suppl; abstr LBA11511)
  87. US Food and Drug Administration: FDA approves new pill to treat certain patients with non-small cell lung cancer. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm
  88. US Food and Drug Administration: Cobas EGFR mutation test v2. fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm504540.htm
  89. Jenkins S, Yang J, Ramalingam S, et al.: 134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC). J Thorac Oncol 11:S153-S154, 2016 (suppl)
  90. Oxnard GR, Thress KS, Alden RS, et al.: Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer. J Clin Oncol 34:3375-3382, 2016
  91. Sacher AG, Paweletz C, Dahlberg SE, et al.: Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2:1014-1022, 2016
  92. Wakelee HA, Gadgeel SM, Goldman JW, et al.: Epidermal growth factor receptor (EGFR) geno-typing of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. J Clin Oncol 34, 2016 (suppl; abstr 9001)
  93. Reckamp KL, Melnikova VO, Karlovich C, et al.: A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol 11:1690-1700, 2016
  94. Karlovich C, Goldman JW, Sun JM, et al.: Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). Clin Cancer Res 22:2386-2395, 2016
  95. Zill OA, Mortimer S, Banks KC, et al.: Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. J Clin Oncol 34, 2016 (suppl; abstr LBA11501)
  96. Tie J, Wang Y, Tomasetti C, et al.: Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:346ra92, 2016
  97. Mirza MR, Monk BJ, Herrstedt J, et al.: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375(22):2154-2164

Previous Section